Latest Articles
‘Suffering in silence’: $49 million to fix problem - news.com.au
‘Suffering in silence’: $49 million to fix problem news.com.au
Published: May 10, 2024, 7 a.m.
'I never imagined it would be this way': What I want my future daughter to know - 9Honey
'I never imagined it would be this way': What I want my future daughter to know 9Honey
Published: May 10, 2024, 7 a.m.
Endometriosis funding boost ‘great news’ with Medicare to cover longer consultations - Sky News Australia
Endometriosis funding boost ‘great news’ with Medicare to cover longer consultations Sky News Australia
Published: May 10, 2024, 7 a.m.
Deep diving into menstrual cycle data to enhance women’s health - Nature.com
Deep diving into menstrual cycle data to enhance women’s health Nature.com
Published: May 10, 2024, 3:25 a.m.
Living With Endometriosis: a Personal Perspective; a Professional Passion - Yale School of Medicine
Living With Endometriosis: a Personal Perspective; a Professional Passion Yale School of Medicine
Published: May 9, 2024, 7 a.m.
Merck's endometrial cancer therapy fails trial - Reuters
Merck's endometrial cancer therapy fails trial Reuters
Published: May 9, 2024, 7 a.m.
Delaware County woman has her miracle baby at 43 after medical setbacks: "I'm so blessed" - CBS News
Delaware County woman has her miracle baby at 43 after medical setbacks: "I'm so blessed" CBS News
Published: May 9, 2024, 7 a.m.
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer AJMC.com Managed Markets Network
Published: May 9, 2024, 7 a.m.
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma
Published: May 9, 2024, 7 a.m.
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio
Published: May 9, 2024, 7 a.m.
Link copied to clipboard!